Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Hadassah Medical Organization
Age
12–70
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Consenting patients (age 12-70) will be eligible for participation in the study involving anti-tumor immunotherapy provided the following criteria are met:
1. Evidence of cancer not expected to be cured with conventional modalities:
Pediatric patients: Chemotherapy-resistant neuroblastoma stage 4 \& sarcomas. Adult patients: Metastatic breast cancer, malignant melanoma, renal cell cancer and selected cases of ovary cancer, gastrointestinal cancer, small-cell and non-small cell lung cancer with non-bulky metastatic disease, metastatic prostate cancer.
2. Patients with measurable disease evaluable for response with anticipated life expectancy \>3 months.
3. Patients must be \>2 weeks off anti-cancer or potentially immunosuppressive treatment.
4. Adequate ambulatory performance status (Karnofsky \>80%; ECOG 0-1) to enable outpatient treatment (see Appendix 1).
5. Compliant and cooperative patients anticipated to be evaluable for response according to investigator's assessment.
6. HLA-noncompatible (partial matched or mismatched) donor available.
You may not be if
Patients will be excluded from participation in the study if any of the following criteria are met:
1. Any of the above criteria are not met.
2. Patients with a significant history or current evidence of potentially severe cardiovascular disease.
3. Hepatic and/or renal failure.
4. Abnormal PT and PTT.
5. Patients with abnormal hemogram (PMN\<1.0x109/L; HB\<10; Plts\<50x109/L)
6. Evidence of serious active infection requiring antibiotic therapy.
7. Evidence of active disease requiring steroid or cytotoxic therapy.
8. Pregnancy.
9. Contraindication for donation due to donor disease: HIV-1; HBsAg positivity.
Clareo Health | Activated Allogeneic Lymphocytes for Induction Graft Versus Tumor Effect in Metastatic Solid Tumors
